Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 35.7% on Tuesday . The stock traded as high as C$0.10 and last traded at C$0.10. 256,639 shares traded hands during trading, an increase of 172% from the average session volume of 94,340 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Up 71.4 %
The stock has a market cap of C$10.45 million, a P/E ratio of -6.00 and a beta of 0.20. The business has a 50-day simple moving average of C$0.08 and a 200-day simple moving average of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Comparing and Trading High PE Ratio Stocks
- 3 Stocks Helping to Bring AI to Healthcare
- Insider Buying Explained: What Investors Need to Know
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
